Jens Homan1, Abel Boerboom1, Edo Aarts1, Kemal Dogan1, Cees van Laarhoven2, Ignace Janssen1, Frits Berends3. 1. Department of Surgery, Rijnstate Hospital, Postal number 1190, 6800TA, Arnhem, The Netherlands. 2. Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands. 3. Department of Surgery, Rijnstate Hospital, Postal number 1190, 6800TA, Arnhem, The Netherlands. fjberends@planet.nl.
Abstract
BACKGROUND: Despite the fact that the RYGB is performed on a broad scale worldwide as a reliable treatment for morbid obesity, there is no uniform technique for this operation. A number of studies have tried to demonstrate an additional weight loss effect by lengthening the alimentary limb, but to no avail. At this moment in time, the role of the biliopancreatic limb on weight loss is for the greater part unknown. The aim of this randomized controlled trial was to compare the effect on weight loss of a long biliopancreatic limb Roux-en-Y gastric bypass (LBP-GB) with a standard RYGB (S-GB). METHODS: A LBP-GB (BPL 150 cm, alimentary limb 75 cm) was compared with a S-GB (BPL 75 cm, alimentary limb 150 cm). One hundred forty-six patients were randomized in two groups. Weight loss, morbidity, reduction of comorbidities, nutritional status, and quality of life were measured during a period of 4 years. RESULTS: Patient characteristics were comparable in both groups. Mean EWL in the LBP-GB group after 12, 24, 36, and 48 months was 81, 85, 78, and 72% respectively versus 71, 73, 68, and 64% in the S-GB group. The %EWL difference between groups was significant as soon as 9 months postoperatively and continued throughout the follow-up period. CONCLUSIONS: While LBP-GB achieved a significant increase in %EWL in the first years after surgery, no difference in long-term %TWL was observed after 4 years. In this study, the advantage of LBP-GB with respect to weight loss is modest, but shows promising gripping points for future improvements in RYGB design.
BACKGROUND: Despite the fact that the RYGB is performed on a broad scale worldwide as a reliable treatment for morbid obesity, there is no uniform technique for this operation. A number of studies have tried to demonstrate an additional weight loss effect by lengthening the alimentary limb, but to no avail. At this moment in time, the role of the biliopancreatic limb on weight loss is for the greater part unknown. The aim of this randomized controlled trial was to compare the effect on weight loss of a long biliopancreatic limb Roux-en-Y gastric bypass (LBP-GB) with a standard RYGB (S-GB). METHODS: A LBP-GB (BPL 150 cm, alimentary limb 75 cm) was compared with a S-GB (BPL 75 cm, alimentary limb 150 cm). One hundred forty-six patients were randomized in two groups. Weight loss, morbidity, reduction of comorbidities, nutritional status, and quality of life were measured during a period of 4 years. RESULTS: Patient characteristics were comparable in both groups. Mean EWL in the LBP-GB group after 12, 24, 36, and 48 months was 81, 85, 78, and 72% respectively versus 71, 73, 68, and 64% in the S-GB group. The %EWL difference between groups was significant as soon as 9 months postoperatively and continued throughout the follow-up period. CONCLUSIONS: While LBP-GB achieved a significant increase in %EWL in the first years after surgery, no difference in long-term %TWL was observed after 4 years. In this study, the advantage of LBP-GB with respect to weight loss is modest, but shows promising gripping points for future improvements in RYGB design.
Entities:
Keywords:
Bariatric surgery; Long biliopancreatic limb; Morbid obesity; Roux-en-Y gastric bypass; Weight loss
Authors: Reuben D Shin; Michael B Goldberg; Allison S Shafran; Samuel A Shikora; Melissa C Majumdar; Scott A Shikora Journal: Obes Surg Date: 2019-03 Impact factor: 4.129
Authors: Mellody I Cooiman; Suzanne I M Alsters; Maeva Duquesnoy; Eric J Hazebroek; Hanne J Meijers-Heijboer; Harvinder Chahal; Johanne Le Beyec-Le Bihan; Karine Clément; Hedi Soula; Alex I Blakemore; Christine Poitou; Mieke M van Haelst Journal: Obes Surg Date: 2022-01-04 Impact factor: 4.129
Authors: M I Cooiman; L Kleinendorst; E O Aarts; I M C Janssen; H K Ploos van Amstel; A I Blakemore; E J Hazebroek; H J Meijers-Heijboer; B van der Zwaag; F J Berends; M M van Haelst Journal: Obes Surg Date: 2020-02 Impact factor: 4.129
Authors: Alexander Dimitri Miras; Anna Kamocka; Belén Pérez-Pevida; Sanjay Purkayastha; Krishna Moorthy; Ameet Patel; Harvinder Chahal; Gary Frost; Paul Bassett; Lidia Castagnetto-Gissey; Lucy Coppin; Nicola Jackson; Anne Margot Umpleby; Stephen Robert Bloom; Tricia Tan; Ahmed Rashid Ahmed; Francesco Rubino Journal: Diabetes Care Date: 2020-11-06 Impact factor: 19.112